Seronegative rheumatoid arthritis (SN RA) poses significant diagnostic and management challenges due to the lack of conventional biomarkers such as rheumatoid factor (RF) and anti-CCP antibodies, complicating timely and accurate diagnosis.
This webinar explores the emerging diagnostic and prognostic value of anti-RA33 autoantibodies (IgG, IgA and IgM) as novel biomarkers, capable of bridging the critical gap in SN RA clinical practice. Through a comprehensive review of existing diagnostic methods and their limitations, participants will understand why innovative biomarkers are urgently needed.
The expert speakers will delve into the historical discovery and usage of RA33 autoantibodies, integrating the latest research evidence demonstrating their effectiveness in clinical practice. Real-world clinical case examples will highlight how incorporating RA33 biomarkers enhances diagnostic accuracy, improves prognosis assessments and ultimately leads to better patient outcomes.
Join this webinar to discover how RA33 biomarkers are transforming clinical decision-making for patients with SN RA.
Speakers

Dr. Alvin F. Wells, MD, PhD, FACP, FACR, Director of Rheumatology, American Medical Group
Dr. Alvin Wells is currently a practicing rheumatologist and the Director of Rheumatology for the American Medical Group in Destin, FL. He is the immediate past Midwest Region Director, Department of Rheumatology for the Advocate Health Medical Group in Franklin, Wisconsin. He is an Assistant Clinical Professor at the Medical College of Wisconsin.
He also maintains his clinical affiliation with Duke University Medical Center in Durham, NC, where he is an Adjunct Assistant Professor. Prior to returning to private practice, Dr. Wells was an Associate Medical Director at Abbott Laboratories where he played a central role in the launch of HUMIRA.
Read more...
A member of the American Telemedicine Association and of the American College of Rheumatology, Dr. Wells has over 25 years of research experience, focusing on chronic inflammatory diseases, such as rheumatoid arthritis and psoriatic arthritis, with an emphasis on connective tissue components, inflammatory mediators, and cytokines. He is the recipient of the 2019 Outstanding Teaching Award from the Medical College of Wisconsin and Ascension St Joseph Hospital. He is the recipient of the 2003 Abbott President’s Award. In 2001, he was honored with the Merck Young Investigator Award, and in 1999 he received the University of South Carolina School of Medicine Distinguished Alumni Award.
Dr. Wells is fluent in Swedish and is an internationally renowned speaker and researcher and has had research support from the Arthritis Foundation and from the Robert Wood Johnson Foundation.
Read Less...

Tyler O’Malley, VP of Clinical Affairs, Bioinformatics and Market Access, Exagen Inc.
Tyler O’Malley serves as VP of Clinical Affairs, Bioinformatics and Market Access at Exagen Inc., a leader in autoimmune testing solutions. In his role, he oversees clinical trials, bioinformatics and medical policy development for Exagen’s current diagnostic portfolio and pipeline of proprietary solutions.
With more than a decade of experience, O’Malley has contributed to more than a dozen clinical trials, focusing on clinical validity and utility evidence for autoimmune diagnostics. His expertise is widely recognized, with numerous publications in esteemed peer-reviewed journals. Notably, he is the first author of one of the largest clinical utility studies in lupus diagnostics.
Read more...
Read Less...
Who Should Attend?
This webinar will appeal to:
- Rheumatologists/Rheumatology Nurse Practitioners/Rheumatology Physician Assistants
- Generalists
- Immunologists
- Healthcare professionals
- Clinical researchers at hospitals and specialist consultants in rheumatology and clinical immunology
- Program leads/Heads of Rheumatology at pharma and biotech companies
What You Will Learn
Attendees will gain insights into:
- Critical diagnostic and prognostic challenges clinicians face when managing SN RA due to the absence of conventional serological biomarkers
- Limitations and gaps of current diagnostic strategies in SN RA and why new biomarker solutions are essential
- Historical perspectives and recent advances regarding RA33 autoantibodies (IgG, IgA and IgM) and their emerging role in clinical practice
- Real-world clinical scenarios illustrating how the inclusion of RA33 biomarkers has improved diagnostic confidence and patient management strategies
- Current research and future directions in RA33 biomarker application, aiming to enhance clinical pathways for diagnosis, prognosis and therapeutic decision-making in RA
Xtalks Partner
Exagen Inc.
Exagen Inc. is a patient-focused and discovery-driven commercial-stage life sciences company. We aid patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions. Our relentless pursuit for laboratory excellence has enabled us to develop next-generation autoimmune testing to help empower physicians and improve patients’ lives.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account